These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 7966200)
1. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. Samaranayake YH; Samaranayake LP J Med Microbiol; 1994 Nov; 41(5):295-310. PubMed ID: 7966200 [TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
5. [Candida krusei (Castellani) Berkhout--a potential pathogen with growing importance]. Otcenásek M; Buchta V Epidemiol Mikrobiol Imunol; 1998 Dec; 47(4):137-40. PubMed ID: 9919813 [TBL] [Abstract][Full Text] [Related]
6. Fungal endophthalmitis. Yu VL; Eller AW Ophthalmology; 1998 Jul; 105(7):1129-30. PubMed ID: 9663211 [No Abstract] [Full Text] [Related]
7. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001 [TBL] [Abstract][Full Text] [Related]
8. Update on Candida krusei, a potential multidrug-resistant pathogen. Jamiu AT; Albertyn J; Sebolai OM; Pohl CH Med Mycol; 2021 Jan; 59(1):14-30. PubMed ID: 32400853 [TBL] [Abstract][Full Text] [Related]
9. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. Silva S; Negri M; Henriques M; Oliveira R; Williams DW; Azeredo J FEMS Microbiol Rev; 2012 Mar; 36(2):288-305. PubMed ID: 21569057 [TBL] [Abstract][Full Text] [Related]
10. Candida dubliniensis, a new fungal pathogen. Gutiérrez J; Morales P; González MA; Quindós G J Basic Microbiol; 2002; 42(3):207-27. PubMed ID: 12111748 [TBL] [Abstract][Full Text] [Related]
12. Candida krusei: biotechnological potentials and concerns about its safety. Yadav JS; Bezawada J; Yan S; Tyagi RD; Surampalli RY Can J Microbiol; 2012 Aug; 58(8):937-52. PubMed ID: 22823163 [TBL] [Abstract][Full Text] [Related]
13. Endogenous Candida endophthalmitis: a case report. Chung YM; Lin JC; Liu JH Zhonghua Yi Xue Za Zhi (Taipei); 1994 Apr; 53(4):239-42. PubMed ID: 8004531 [TBL] [Abstract][Full Text] [Related]
14. Recurrent Candida albicans endophthalmitis in an immunocompromised host. Weinstein O; Levy J; Lifshitz T Can J Ophthalmol; 2007 Feb; 42(1):154-5. PubMed ID: 17361271 [No Abstract] [Full Text] [Related]
15. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. McQuillen DP; Zingman BS; Meunier F; Levitz SM Clin Infect Dis; 1992 Feb; 14(2):472-8. PubMed ID: 1554833 [TBL] [Abstract][Full Text] [Related]
16. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. Hope W; Morton A; Eisen DP J Hosp Infect; 2002 Jan; 50(1):56-65. PubMed ID: 11825053 [TBL] [Abstract][Full Text] [Related]
17. Changing spectrum of invasive candidiasis and its therapeutic implications. Singh N Clin Microbiol Infect; 2001; 7 Suppl 2():1-7. PubMed ID: 11525214 [TBL] [Abstract][Full Text] [Related]